ZB022 / Zenas BioPharma - LARVOL DELTA

Early development programs (The Manila Times) - "ZB022, an oral, brain-penetrant, TYK2-JH2 inhibitor: IND enabling studies ongoing: Subject to the results of IND enabling studies, Zenas expects to initiate a Phase 1 clinical study in 2027...ZB014, a half-life extended, anti-CD19 and FcγRIIb monoclonal antibody (mAb): Zenas expects to advance the program into Phase 1 clinical development in 2027."

New P1 trial • Preclinical • Immunology • Inflammation

Early development programs (GlobeNewswire) - "IND enabling studies ongoing: Subject to the results of IND enabling studies, Zenas expects to initiate a Phase 1 clinical study in 2027....Developed using half-life extension technology for mAbs, and based on preclinical study results, ZB014 has the potential to provide the clinical activity and safety profile observed with obexelimab while offering a once-monthly dosing schedule. Zenas expects to advance the program into Phase 1 clinical development in 2027."

IND • Immunology • Inflammation

Other pipeline updates (GlobeNewswire) - "Zenas expects initiation of Phase 1 clinical development for ZB021 in the second quarter of 2026 and to report initial clinical data by year-end 2026. Pending Phase 1 data, Zenas expects to advance development of ZB021 for rheumatic and/or dermatologic diseases....Zenas expects to complete IND enabling studies for ZB022 in 2026 and then advance the program into Phase 1 clinical development upon IND clearance."

New P1 trial • P1 data • Preclinical • Dermatology • Immunology • Inflammation • Rheumatology

In Investigational New Drug (IND) enabling studies: Zenas expects to submit an IND and initiate Phase 1 clinical development in 2026. Pending Phase 1 data, Zenas expects to advance development of ZB022 for neurologic diseases. (GlobeNewswire)

IND • New P1 trial • CNS Disorders

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis (GlobeNewswire) - "Zenas also secured rights to a novel, oral, IL-17AA/AF inhibitor, and an oral, brain-penetrant, TYK2 inhibitor....Under the license agreement, Zenas will pay InnoCare upfront and near-term milestone payments of up to $100 million in cash, including milestone achievements expected in 2026, and up to 7,000,000 shares of Zenas common stock, including shares issuable upon a milestone expected to be achieved in early 2026."

Licensing / partnership • Multiple Sclerosis

A novel oral IL-17AA/AF inhibitor, and an oral, brain-penetrant, TYK2 inhibitor, expected to begin Phase 1 clinical trials in 2026 (GlobeNewswire)

New P1 trial • Immunology